Tenax Therapeutics, Inc. (TENX) |
|
0.282 -0.003 (-1.05%)
|
08-18 05:42 |
|
Open: |
0.2999 |
Pre. Close: |
0.285 |
|
High:
|
0.31 |
Low:
|
0.26 |
|
Volume:
|
225,513 |
Market Cap:
|
7(M) |
|
|
|
|
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.31 - 0.32 |
0.32 - 0.32 |
|
Low:
|
0.25 - 0.26 |
0.26 - 0.26 |
|
Close:
|
0.28 - 0.28 |
0.28 - 0.29 |
|
Technical analysis |
as of: 2022-08-17 4:27:08 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.34 One year: 0.38 |
| Support: |
Support1: 0.25 Support2: 0.2 |
| Resistance: |
Resistance1: 0.29 Resistance2: 0.32 |
| Pivot: |
0.27  |
| Moving Average: |
MA(5): 0.29  MA(20): 0.27
MA(100): 0.51 MA(250): 0.88 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 48.6 %D(3): 58 |
| RSI: |
RSI(14): 41.7 |
| 52-week: |
High: 1.95 Low: 0.23 |
| Average Vol(K): |
3-Month: 208 (K) 10-Days: 134 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TENX ] has closed below upper band by 45.5%. Bollinger Bands are 66.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Thu, 11 Aug 2022
Have $1.4 million? You could buy the Johnstown Galleria, now up for auction - TribDem.com
Tue, 09 Aug 2022
River North's Hotel Felix loan heads to auction - Crain's Chicago Business
Tue, 09 Aug 2022
Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com - Defense World
Thu, 04 Aug 2022
What's Next for Very Bullish Rated TenX (PAY)? - InvestorsObserver
Mon, 01 Aug 2022
StockNews.com Begins Coverage on Tenax Therapeutics (NASDAQ:TENX) - Defense World
Tue, 26 Jul 2022
Projects - Community engagement enhances urban spaces - LEDs Magazine
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
25 (M) |
| Shares Float |
16 (M) |
|
% Held by Insiders
|
36.2 (%) |
|
% Held by Institutions
|
32 (%) |
|
Shares Short
|
12 (K) |
|
Shares Short P.Month
|
13 (K) |
Stock Financials |
|
EPS
|
-0.5 |
|
EPS Est Next Qtl
|
-0.08 |
|
EPS Est This Year
|
-0.37 |
|
EPS Est Next Year
|
-0.29 |
|
Book Value (p.s.)
|
0.05 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-158.2 |
|
Return on Equity (ttm)
|
-487 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.42 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-11 (M) |
|
Levered Free Cash Flow
|
-5 (M) |
Stock Valuations |
|
PE Ratio
|
-0.58 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
4.7 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.68 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2018-02-25 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
